沃诺普评估:针对早期发作的发症开发有针对性的治疗方法
Pablo M Casillas-Espinosa1,2,3, Jennifer C Wong4, Wanda Grabon5,6
1Department of Neuroscience, Central Clinical School, Monash University, Melbourne, Victoria, Australia.
Epilepsia
|November 19, 2024
概括
新的精准医学方法为早期发作提供了希望,这是严重的神经系统疾病的一组. 研究正在探索针对性疗法,如小分子和对抗药性和发育迟缓的基因治疗.
科学领域:
- 神经科学和遗传学 在神经科学和遗传学.
- 的研究研究.
背景情况:
- 早期是一种多样化的疾病群体,通常导致抗药性发作,发育迟缓和其他严重的并发症.
- 基因测序的进步已经确定了许多致病基因,de novo变异是疾病病因学的重要因素.
- 目前对这些疾病的治疗选择有限,这凸显了对创新治疗策略的需求.
研究的目的:
- 总结了在神经生物学研讨会 (WONOEP XVI) 上讨论的新型治疗策略.
- 突出精准医学的进步,用于针对性治疗早期发作的.
主要方法:
- 综述了WONOEP XVI的演讲和讨论,重点是新兴疗法.
- 通过基因组,整个外基因组和整个基因组测序来探索遗传发现.
- 讨论各种治疗点,包括分子,细胞和遗传方法.
主要成果:
- 鉴定早期患者的一个子集的遗传基础.
- 探索特定的治疗途径:用于新生儿发作的化物载体抑制剂,用于儿童缺席的奥雷克辛能信号,以及用于德拉维特综合征的能量代谢标.
- 考虑使用大麻素受体2型,乙胆酶抑制剂,细胞疗法和基于RNA的疗法来治疗早期.
结论:
- 精准医学方法,包括小分子和基因疗法,对治疗早期发作的有前途.
- 对新型治疗策略的持续研究为患有这些复杂神经系统疾病的患者提供了改善结果的希望.
- 鉴定基因基础对于开发有针对性和有效的治疗方法至关重要.
相关概念视频
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Arteries of the Lower Limbs
178
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
178
Antiepileptic Drugs: Glutamate Antagonists
284
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
284
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
253
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
253
Antiepileptic Drugs: GABAergic Pathway Potentiators
334
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
334
Antiepileptic Drugs: Potassium Channel Activators
147
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
147


